Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma - 07/09/11
Abstract |
Background: The results of a recent study suggested that ultraviolet A1 radiation (UVA1R; 340-400 nm) phototherapy for atopic dermatitis works through induction of apoptosis in skin-infiltrating helper T cells, indicating the possibility that other helper T cell–mediated skin diseases may respond to UVA1R as well. Objective: The purpose of this open pilot study was to assess the therapeutic effectiveness of UVA1 phototherapy for cutaneous T-cell lymphoma (CTCL). Methods: UVA1 phototherapy was used as monotherapy in patients (n = 3) with histologically proven CTCL (stages IA and IB). For daily whole body UVA1 irradiations, either a high-dose (n = 2; 130 J/cm2 UVA1 per exposure) or medium-dose (n = l; 60 J/cm2 UVA1) regimen was used. Therapeutic effectiveness was assessed clinically and histologically. Results: In each of the 3 patients, skin lesions began to resolve after only a few UVA1 radiation exposures. Complete clearance was observed between 16 and 20 exposures, regardless of whether the high- or medium-dose regimen had been employed. Conclusion: These studies suggest that patients with CTCL stages IA and IB can be treated effectively with UVA1 phototherapy. (J Am Acad Dermatol 1999;41:47-50.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Jean Krutmann, MD, Professor of Dermatology, Clinical and Experimental Photodermatology, Department of Dermatology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany. |
|
0190-9622/99/$8.00 + 0 16/1/97582 |
Vol 41 - N° 1
P. 47-50 - juillet 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?